{"transactions":[{"id":1155841,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2025-05-08T20:26:34.000Z","date":"2025-05-06","kind":"grant","planned":false,"acquired":true,"shares":7183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total includes the automatic reinvestment of dividends."}],"balance_after":35847,"source":{"system":"sec-edgar","filing":"0001062993-25-008900","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000106299325008900/form4.xml","form_type":"4"}},{"id":1168558,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-21T17:00:17.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the \"Merger Agreement\"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. (\"Parent\"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each outstanding option vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such option, (i) an amount in cash equal to the excess, if any, of the Cash Consideration over the per share exercise price of such option and (ii) one CVR. Notwithstanding the foregoing, (a) any option with a per share exercise price equal to or greater than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was canceled for no consideration and (b) any option with a per share exercise price that is equal to or greater than the Cash Consideration but less than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was converted into the right to receive one CVR with respect to each share of Common Stock underlying such option, subject to the terms of the CVR Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the \"Merger Agreement\"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. (\"Parent\"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each outstanding option vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such option, (i) an amount in cash equal to the excess, if any, of the Cash Consideration over the per share exercise price of such option and (ii) one CVR. Notwithstanding the foregoing, (a) any option with a per share exercise price equal to or greater than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was canceled for no consideration and (b) any option with a per share exercise price that is equal to or greater than the Cash Consideration but less than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was converted into the right to receive one CVR with respect to each share of Common Stock underlying such option, subject to the terms of the CVR Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the \"Merger Agreement\"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. (\"Parent\"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, each outstanding option vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such option, (i) an amount in cash equal to the excess, if any, of the Cash Consideration over the per share exercise price of such option and (ii) one CVR. Notwithstanding the foregoing, (a) any option with a per share exercise price equal to or greater than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was canceled for no consideration and (b) any option with a per share exercise price that is equal to or greater than the Cash Consideration but less than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was converted into the right to receive one CVR with respect to each share of Common Stock underlying such option, subject to the terms of the CVR Agreement."}],"balance_after":0,"derivative":{"exercise_price":6.6,"underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-25-056367","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000095017025056367/ownership.xml","form_type":"4"}},{"id":1168557,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-21T17:00:17.000Z","date":"2025-04-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40216,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the \"Merger Agreement\"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. (\"Parent\"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-056367","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000095017025056367/ownership.xml","form_type":"4"}},{"id":1507430,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-21T16:48:30.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":15906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":40216,"source":{"system":"sec-edgar","filing":"0001610717-24-000252","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000161071724000252/form4.xml","form_type":"4"}},{"id":1522891,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2024-05-09T20:33:36.000Z","date":"2024-05-07","kind":"grant","planned":false,"acquired":true,"shares":5952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total includes the automatic reinvestment of dividends."}],"balance_after":27901,"source":{"system":"sec-edgar","filing":"0001062993-24-009782","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000106299324009782/form4.xml","form_type":"4"}},{"id":1810109,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:10:43.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4273,"price":7.51,"value":32090.23,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":7.41,"expiration_date":"2026-07-13","underlying":"Common Stock","underlying_shares":4273},"source":{"system":"sec-edgar","filing":"0001415889-23-012135","document":"form4-08112023_040821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000141588923012135/form4-08112023_040821.xml","form_type":"4"}},{"id":1810108,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:10:43.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":4.9984,"value":3413.9072,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":9.9216,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012135","document":"form4-08112023_040821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000141588923012135/form4-08112023_040821.xml","form_type":"4"}},{"id":1810107,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:10:43.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":6.6439,"value":4537.7837,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":8.2761,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012135","document":"form4-08112023_040821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000141588923012135/form4-08112023_040821.xml","form_type":"4"}},{"id":1882999,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-22T16:20:22.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024"}],"balance_after":8888,"derivative":{"exercise_price":0.6366,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-23-008496","document":"form4-05222023_040514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000141588923008496/form4-05222023_040514.xml","form_type":"4"}},{"id":1885138,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-19T18:37:33.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":8361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":24310,"source":{"system":"sec-edgar","filing":"0001610717-23-000060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000161071723000060/form4.xml","form_type":"4"}},{"id":1905384,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2023-05-04T20:34:17.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":4573,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant."}],"balance_after":21336,"source":{"system":"sec-edgar","filing":"0001062993-23-010210","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000106299323010210/form4.xml","form_type":"4"}},{"id":2000428,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-22T17:07:45.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":8918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the issuer."}],"balance_after":15949,"source":{"system":"sec-edgar","filing":"0001567619-23-003531","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000156761923003531/doc1.xml","form_type":"4"}},{"id":2253859,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T17:01:00.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023."}],"balance_after":8888,"derivative":{"exercise_price":0.7632,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-22-005830","document":"form4-05272022_050538.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000141588922005830/form4-05272022_050538.xml","form_type":"4"}},{"id":2281640,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2022-05-05T21:25:09.000Z","date":"2022-05-03","kind":"grant","acquired":true,"shares":2706,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant."}],"balance_after":16389,"source":{"system":"sec-edgar","filing":"0001062993-22-011689","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000106299322011689/form4.xml","form_type":"4"}},{"id":2486552,"issuer":{"id":80621,"kind":"organization","name":"Paragon 28, Inc.","symbol":"FNA"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T16:28:57.000Z","date":"2021-10-14","kind":"grant","acquired":true,"shares":7031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,031 RSUs."}],"balance_after":7031,"source":{"system":"sec-edgar","filing":"0001567619-21-021591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000156761921021591/doc1.xml","form_type":"4"}},{"id":2653844,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T07:15:29.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":8888,"price":9.97,"value":88613.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022."}],"balance_after":8888,"derivative":{"exercise_price":9.97,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-21-003241","document":"form4-06282021_070613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000141588921003241/form4-06282021_070613.xml","form_type":"4"}},{"id":2726168,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2021-05-06T22:01:03.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":2230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant."}],"balance_after":13495,"source":{"system":"sec-edgar","filing":"0001174532-21-000001","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000117453221000001/edgar.xml","form_type":"4"}},{"id":2955389,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-07T17:48:24.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on the earlier of July 14, 2021 or the Company's next annual meeting of stockholders."}],"balance_after":8888,"derivative":{"exercise_price":18,"expiration_date":"2030-12-02","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001104659-20-132938","document":"tm2037869-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000110465920132938/tm2037869-5_4seq1.xml","form_type":"4"}},{"id":3159077,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2020-05-07T20:19:25.000Z","date":"2020-05-05","kind":"grant","acquired":true,"shares":2197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant."}],"balance_after":11133,"source":{"system":"sec-edgar","filing":"0001174532-20-000001","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000117453220000001/edgar.xml","form_type":"4"}},{"id":3534708,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2019-05-09T20:11:21.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":2412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of fully vested shares of common stock of Baxter International Inc. subject to the terms and conditions of the applicable grant."}],"balance_after":8842,"source":{"system":"sec-edgar","filing":"0001174532-19-000001","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000117453219000001/edgar.xml","form_type":"4"}},{"id":3878987,"issuer":{"id":11998,"kind":"organization","name":"REVA Medical, Inc.","symbol":"RVA.AX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T20:05:19.000Z","date":"2018-06-29","kind":"purchase","acquired":true,"shares":16359.6,"price":1.53,"value":25030.188,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the purchase of 163,596 of the Issuer's CHESS Depositary Interests (CDIs) trading on the Australian Securities Exchange."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction."}],"balance_after":49359.6,"source":{"system":"sec-edgar","filing":"0001209191-18-040516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000120919118040516/doc4.xml","form_type":"4"}},{"id":3926022,"issuer":{"id":11998,"kind":"organization","name":"REVA Medical, Inc.","symbol":"RVA.AX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-18T21:10:19.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":6917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable on May 16, 2019."}],"balance_after":86917,"derivative":{"exercise_price":1.96,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":6917},"source":{"system":"sec-edgar","filing":"0001209191-18-031616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000120919118031616/doc4.xml","form_type":"4"}},{"id":3926021,"issuer":{"id":11998,"kind":"organization","name":"REVA Medical, Inc.","symbol":"RVA.AX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-18T21:10:19.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in three (3) equal annual installments beginning on May 16, 2019."}],"balance_after":80000,"derivative":{"exercise_price":1.96,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-18-031616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1174532/000120919118031616/doc4.xml","form_type":"4"}},{"id":3940410,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2018-05-10T20:24:18.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":2664,"price":69.45,"value":185014.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of 2,664 fully vested shares of common stock of Baxter International Inc. (the \"Company\"), subject to the terms and conditions of the applicable grant."}],"balance_after":6365,"source":{"system":"sec-edgar","filing":"0001174532-18-000001","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000117453218000001/edgar.xml","form_type":"4"}},{"id":4334481,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2017-05-04T20:58:59.000Z","date":"2017-05-02","kind":"grant","acquired":true,"shares":3233,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person received a grant of 3,233 fully vested shares of common stock of Baxter International Inc. (the \"Company\"), subject to the terms and conditions of the applicable grant."}],"balance_after":3664,"source":{"system":"sec-edgar","filing":"0001174532-17-000005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000117453217000005/edgar.xml","form_type":"4"}},{"id":4463353,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-08T21:18:10.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":1060,"price":48.35,"value":51251.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The date exercisable is the date of the 2017 annual meeting of stockholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The date exercisable is the date of the 2017 annual meeting of stockholders."}],"balance_after":1060,"derivative":{"exercise_price":48.35,"underlying":"Common Stock, $1 par value","underlying_shares":1060},"source":{"system":"sec-edgar","filing":"0001174532-17-000004","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/10456/000117453217000004/edgar.xml","form_type":"4"}},{"id":4463352,"issuer":{"id":1707,"kind":"organization","name":"BAXTER INTERNATIONAL INC","symbol":"BAX"},"owners":[{"id":80047,"kind":"person","name":"Oesterle Stephen N.","position":1,"cik":"0001174532","reported_name":"Oesterle Stephen N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $1 par value","published_at":"2017-02-08T21:18:10.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":430,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of 430 restricted stock units which are scheduled to vest on the date of the 2017 annual meeting of stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person received a grant of 430 restricted stock units which are scheduled to vest on the date of the 2017 annual meeting of stockholders."}],"balance_after":430,"source":{"system":"sec-edgar","filing":"0001174532-17-000004","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/10456/000117453217000004/edgar.xml","form_type":"4"}}]}